- Home
- OPT vs GDO Comparison
OPT vs GDO Comparison
Compare OPT & GDO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPT
- GDO
- Stock Information
- Founded
- OPT 1984
- GDO 2009
- Country
- OPT Australia
- GDO United States
- Employees
- OPT N/A
- GDO N/A
- Industry
- OPT Biotechnology: Biological Products (No Diagnostic Substances)
- GDO Finance Companies
- Sector
- OPT Health Care
- GDO Finance
- Exchange
- OPT Nasdaq
- GDO Nasdaq
- Market Cap
- OPT 201.5M
- GDO 182.8M
- IPO Year
- OPT 2020
- GDO N/A
- Fundamental
- Price
- OPT $3.24
- GDO $12.90
- Analyst Decision
- OPT Strong Buy
- GDO
- Analyst Count
- OPT 2
- GDO 0
- Target Price
- OPT $14.00
- GDO N/A
- AVG Volume (30 Days)
- OPT 10.8K
- GDO 39.4K
- Earning Date
- OPT 08-30-2024
- GDO 01-01-0001
- Dividend Yield
- OPT N/A
- GDO 9.81%
- EPS Growth
- OPT N/A
- GDO N/A
- EPS
- OPT N/A
- GDO N/A
- Revenue
- OPT $261,859.00
- GDO N/A
- Revenue This Year
- OPT N/A
- GDO N/A
- Revenue Next Year
- OPT $55,563.16
- GDO N/A
- P/E Ratio
- OPT N/A
- GDO N/A
- Revenue Growth
- OPT N/A
- GDO N/A
- 52 Week Low
- OPT $1.60
- GDO $11.21
- 52 Week High
- OPT $4.40
- GDO $13.04
- Technical
- Relative Strength Index (RSI)
- OPT 70.30
- GDO 70.26
- Support Level
- OPT $2.84
- GDO $12.78
- Resistance Level
- OPT $3.19
- GDO $12.79
- Average True Range (ATR)
- OPT 0.14
- GDO 0.05
- MACD
- OPT 0.01
- GDO -0.01
- Stochastic Oscillator
- OPT 100.00
- GDO 100.00
About OPT Opthea Limited
Opthea Ltd operates in one industry being the medical technology and healthcare. It is focused primarily on developing biological therapeutics for eye diseases. The company is developing a novel biologic therapy, OPT-302, for the treatment of eye diseases. Its products are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors C and D and R3 targets. Opthea's development activities are based on an intellectual property portfolio covering key targets Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.
About GDO Western Asset Global Corporate Defined Opportunity Fund Inc.
Western Asset Global Corp Defined Opp is a closed-end management investment company with a primary investment objective to provide current income. Its secondary objective is to seek capital appreciation. The Fund invests in the United States and foreign corporate fixed-income securities of varying maturities.